View in EDS PDF Full Text

Uso de N-acetilcisteína en pacientes que desarrollaron hepatitis por medicamentos antituberculosos: revisión sistemática.

Saved in:
Bibliographic Details
Title: Uso de N-acetilcisteína en pacientes que desarrollaron hepatitis por medicamentos antituberculosos: revisión sistemática.
Alternate Title: Use of N-acetylcysteine in patients with hepatitis by antitubercular agents: systematic review.
Authors: JULIÁN ARISTIZÁBAL-HERNÁNDEZ, JOSÉ1 josej.aristizabal@upb.edu.co, MARÍA BRAVO-ANDRADE, ANA2 anabravo3@hotmail.com, HENAO-VILLADA, ALEJANDRO2 alejandro99henao@gmail.com, MAZO-CAÑOLA, ANDREA2, HERNANDO DONADO-GÓMEZ, JORGE3 jorge.donado@upb.edu.co
Source: Salud Uninorte. sep-dic2023, Vol. 39 Issue 3, p1017-1033. 17p.
Subjects: ANTITUBERCULAR agents, CLINICAL trials, CINAHL database, DRUG side effects, PLACEBOS
Abstract (English): The aim of this systematic review was to estimate the effectiveness of N-Acetylcysteine in the treatment of hepatotoxicity induced by antitubercular agents, we included randomized clinical trials, there was no language nor publication status restriction, published until December 2021. The searched databases were CENTRAL, CINAHL, LILACS, MEDLINE, Pubmed, Scielo, Scopus y Web of Science; out of 33 articles found, one of them met the inclusion criteria and had low bias risk. The time to biochemical resolution was 7,5 days (IQR 5,5-11) in the treatment arm, and 8 (IQR 5-13) in the placebo arm. Time of hospital stay was 9 days (IQR 6-15) in the treatment arm, and 18 (IQR 10-25) in the placebo arm. Mortality (14 %) didn't differ between groups. Further clinical trials may be needed to determine the therapeutic role of N-acetylcysteine in patients with drug-induced liver injury caused by antituberculous agents. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): El objetivo de esta revisión sistemática fue estimar la efectividad de la N-acetilcisteína en el tratamiento de hepatotoxicidad por antituberculosos; se incluyeron ensayos clínicos controlados aleatorizados, sin restricciones de idioma ni estado de publicación; se tuvieron en cuenta estudios publicados hasta diciembre de 2022. Búsqueda en bases de datos bibliográficas: CENTRAL, CINAHL, LILACS, MEDLINE, Pubmed, Scielo, Scopus y Web of Science; de 33 artículos encontrados, uno cumplió los criterios de inclusión con bajo riesgo de sesgos. El tiempo a mejoría bioquímica del grupo intervención fue 7,5 días (RIQ 5,5-11) y en el grupo placebo 8 (RIQ 5-13). El tiempo de estancia hospitalaria en el grupo intervención fue 9 días (RIQ 6-15) y en el grupo placebo 18 (RIQ 10-25). La mortalidad no difirió entre grupos y fue 14 %. No es posible concluir sobre el efecto terapéutico de la N-acetilcisteína en pacientes con DILI por antituberculosos, lo cual justifica realizar ensayos clínicos. [ABSTRACT FROM AUTHOR]
Copyright of Salud Uninorte is the property of Fundacion Universidad del Norte and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
Description
Abstract:The aim of this systematic review was to estimate the effectiveness of N-Acetylcysteine in the treatment of hepatotoxicity induced by antitubercular agents, we included randomized clinical trials, there was no language nor publication status restriction, published until December 2021. The searched databases were CENTRAL, CINAHL, LILACS, MEDLINE, Pubmed, Scielo, Scopus y Web of Science; out of 33 articles found, one of them met the inclusion criteria and had low bias risk. The time to biochemical resolution was 7,5 days (IQR 5,5-11) in the treatment arm, and 8 (IQR 5-13) in the placebo arm. Time of hospital stay was 9 days (IQR 6-15) in the treatment arm, and 18 (IQR 10-25) in the placebo arm. Mortality (14 %) didn't differ between groups. Further clinical trials may be needed to determine the therapeutic role of N-acetylcysteine in patients with drug-induced liver injury caused by antituberculous agents. [ABSTRACT FROM AUTHOR]
ISSN:01205552
DOI:10.14482/sun.39.03.005.258